The pet medication manufacturers industry in Europe focuses on developing veterinary pharmaceuticals, health supplements, and wellness products aimed at improving animal health. Companies in this sector range from established pharmaceutical giants to innovative startups, all contributing to advancements in pet healthcare. The market places importance on preventive care and effective treatments for pets, reflecting a growing trend towards health-conscious pet ownership. With increasing pet ownership rates and a heightened awareness of animal wellbeing, the industry is leaning towards more specialized and targeted medications. This exciting trajectory is expected to foster innovation and create significant opportunities for growth.


This comprehensive list features 18 prominent investors in the pet medication manufacturers industry, showcasing a mix of venture capitalists and corporate giants. Headquartered throughout Europe, these investors vary in size, from small startups to large corporations, and have been active in deal-making. In 2024 alone, these investors collectively put their money into dozens of ambitious projects, aimed at advancing pet health solutions. Founded in periods ranging from the 1940s to the 2010s, this unique group exhibits rich experiences and visions for the future of pet healthcare investments.


Top 18 Pet Medication Manufacturers Investors in Europe


1. CVS Group plc

  • Website: cvsukltd.co.uk
  • Type: Corporate
  • Headquarters: Diss, England, United Kingdom (UK)
  • Founded year: 1999
  • Headcount: 5001-10000
  • Number of deals in 2024: 1
  • LinkedIn:

CVS Group plc is a corporate investor based in Diss, England, UK, founded in 1999. The company specializes in veterinary services, providing comprehensive care for small animals, equine, and farm animals. They offer a range of services including veterinary care, pet insurance, and health programs, catering to pet owners and farmers alike. CVS Group has been active in expanding its network through strategic acquisitions, including Studley Road Veterinary Surgery in 2000, Archway Veterinary Practice in 2013, and several others such as Putlands Veterinary Surgery and Alver Veterinary Group. These acquisitions reflect their commitment to enhancing veterinary services and support for pet health, positioning them as a significant player in the pet medication and healthcare industry.


2. Bpifrance French Tech Accélération


Bpifrance French Tech Accélération is a venture capital investor based in Paris, Île-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through a range of services, including direct funding, export credit insurance, and private equity investments. They aim to foster entrepreneurship and innovation through coaching and partnerships, helping businesses navigate growth and international expansion. Notably, Bpifrance has made significant investments in the pet medication sector, including Vetbiolix, which raised $4,230,248 in December 2024 and $2,771,671 in September 2024, and Enalees, which raised $16,307,255 in July 2024. These transactions highlight Bpifrance's commitment to supporting innovation in the pet health industry, making them a relevant investor in this space.


3. Novo Holdings

  • Website: novoholdings.dk
  • Type: Venture Capital
  • Headquarters: Hellerup, Denmark
  • Founded year: 1999
  • Headcount: 51-200
  • Number of deals in 2024: 45
  • LinkedIn: novo-a-s

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages the assets of the Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Among their notable transactions, they participated in a Series B financing round for Invetx, which raised US$60.5 million to advance its monoclonal antibody pipeline targeting chronic and serious diseases in dogs and cats. This investment highlights their engagement in the pet medication sector. Additionally, they have invested in Bactolife, which, while not directly related to pet medication, showcases their broader commitment to innovative life science solutions. Overall, Novo Holdings is a significant player in the life sciences investment landscape, with a growing interest in pet health solutions.


4. Almi

  • Website: almi.se
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 201-500
  • Number of deals in 2024: 7
  • LinkedIn: almi-ab

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance the growth and competitiveness of these businesses by offering tailored financial solutions and guidance. Among its notable transactions, Almi has invested in PreVet, which raised $1,762,180 in a venture round in March 2021, indicating a direct interest in the pet medication sector. Additionally, Almi has participated in funding rounds for other innovative startups, such as Amferia, which focuses on wound care technology, showcasing its commitment to supporting health-related innovations. This diverse investment strategy positions Almi as a significant player in the venture capital landscape, particularly for companies that may intersect with the pet medication industry.


5. Enterprise Ireland


Enterprise Ireland is a public entity that serves as the Irish government's enterprise development agency, founded in 1998. It supports Irish businesses at all stages of their growth journey by providing funding, advisory services, and market access assistance. The agency focuses on helping companies scale and compete internationally across various industries, including technology and manufacturing. In recent years, Enterprise Ireland has been active in the pet sector, providing grants to companies such as Pet Food Depot and participating in funding rounds for Soopa Pets, which operates in the pet care market. These transactions reflect their commitment to fostering growth in the pet industry, making them a relevant investor in the context of pet medication manufacturers.


6. Crowdcube

  • Website: crowdcube.com
  • Type: Corporate
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 2010
  • Headcount: 51-200
  • Number of deals in 2024: 3
  • LinkedIn: crowdcube-limited

Crowdcube is a London-based crowdfunding platform founded in 2010 that enables businesses to raise capital through equity investments. It connects startups and SMEs with potential investors, facilitating the funding process. The platform promotes diversity and inclusion within its workforce while providing investment management services to its clients. Notably, Crowdcube has been involved in several transactions within the pet industry, including HOWND, which raised $134,576 in 2021, Pawprint with $433,724 in 2020, Poppy’s Picnic at $802,553 in 2018, PitPat at $971,392 in 2016, and Aristopet at $182,144 in 2020. These investments highlight Crowdcube's engagement with companies that contribute to pet health and wellness, making it a relevant player in the pet medication manufacturers space.


7. Scottish Enterprise


Scottish Enterprise is a public entity based in Glasgow, Scotland, established in 1991, dedicated to fostering economic development in Scotland. It provides a variety of services, including funding, business development advice, and support for innovation and exports. In 2024, Scottish Enterprise was involved in 55 investments, showcasing its active role in supporting businesses. Notably, it participated in the Series A funding of MI:RNA, a veterinary diagnostics company, which raised $4 million to enhance animal health testing. Additionally, Scottish Enterprise has a history of investing in companies like Aquapharm Biodiscovery, which has raised significant funds for biotechnology advancements, and ILC Therapeutics, which focuses on developing treatments for viral infections. These transactions highlight Scottish Enterprise's commitment to supporting innovations that can impact the pet medication sector.


8. Andera Partners

  • Website: anderapartners.com
  • Type: Private Equity
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1953
  • Headcount: 51-200
  • Number of deals in 2024: 10
  • LinkedIn: anderapartners

Andera Partners is a private equity firm based in Paris, Île-De-France, France, founded in 1953. The firm specializes in investment management and provides financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. Notably, Andera Partners has been involved in several transactions relevant to the pet industry, such as their investment in Mondial Pet Distribution, which raised over $16 million in 2016. This investment highlights their engagement in the pet sector, which encompasses pet medications. Additionally, they have participated in funding rounds for biotech firms like ReViral, indicating their broader interest in life sciences, which may intersect with pet health and medication. Their diverse investment strategies are tailored to meet the specific needs of their portfolio companies, suggesting they are adaptable and open to opportunities in emerging markets, including pet medications.


9. Seventure Partners

  • Website: seventure.fr
  • Type: Venture Capital
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1997
  • Headcount: 11-50
  • Number of deals in 2024: 21
  • LinkedIn: seventure-partners

Seventure Partners is a Paris-based venture capital firm founded in 1997, specializing in managing funds for innovative companies primarily in the digital technology and life sciences sectors. They focus on supporting startups and growth-stage companies through strategic funding. Among their notable transactions, Seventure led the investment in ViroVet, a Belgian biopharmaceutical company that raised over 6 million euros to develop its veterinary product portfolio. Additionally, they participated in the funding of Proteon Pharmaceuticals, which is dedicated to reducing antibiotic use in animal agriculture, showcasing their commitment to advancing animal health. These investments highlight Seventure's active role in the veterinary and pet medication space, reinforcing their relevance in this industry.


10. EQT Group

  • Website: eqtgroup.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 1001-5000
  • Number of deals in 2024: 30
  • LinkedIn: eqt-partners

EQT Group is a prominent private equity firm based in Stockholm, Sweden, founded in 1994. The firm specializes in a diverse range of investment strategies, including private equity, infrastructure, real estate, growth equity, and venture capital. EQT serves institutional investors by providing expertise in managing varied investment portfolios across multiple sectors and geographies. Notably, EQT has made substantial investments in the veterinary care sector, including IVC Evidensia, Europe's largest veterinary care provider, and Evidensia Djursjukvård, the Nordic market leader in veterinary services. They also acquired Independent Vetcare, the third largest veterinary services provider in the UK. Furthermore, EQT's investment in Bought By Many, a leading pet insurance provider, underscores their engagement in the pet care industry, which is closely linked to pet medication. These transactions reflect EQT's strategic focus on the pet care and veterinary services sectors, making them a significant player in the pet medication landscape.


11. 3i Group plc

  • Website: 3i.com
  • Type: Private Equity
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 1945
  • Headcount: 201-500
  • Number of deals in 2024: 3
  • LinkedIn: 3i-group-plc

3i Group plc is a London-based private equity firm founded in 1945, specializing in private equity and infrastructure investments. The firm focuses on providing capital and expertise to mid-market companies, helping them grow sustainably. With a strong international presence and a diverse portfolio, 3i Group aims to create value for its stakeholders through strategic investments. Among their notable transactions, 3i Group acquired Phibro Animal Health in 2008, a company that develops and markets products for animal health, which aligns closely with the pet medication sector. Additionally, in 2020, they acquired a majority stake in MPM, a premium natural pet food company, further demonstrating their involvement in the pet industry. These investments highlight 3i Group's strategic interest in companies that contribute to pet health and nutrition, reinforcing their relevance as an investor in the pet medication manufacturers industry.


12. Swedencare

  • Website: swedencare.com
  • Type: Corporate
  • Headquarters: Malmo, Skåne, Sweden
  • Founded year: 2000
  • Headcount: 11-50
  • Number of deals in 2024: 1
  • LinkedIn: swedencare

Swedencare is a corporate investor based in Malmo, Skåne, Sweden, specializing in pet health products. Founded in 2000, the company offers a range of dietary supplements aimed at improving the health of pets, including dogs, cats, and horses, with a focus on issues such as dental care and anxiety. Swedencare operates an online store for direct consumer sales. The company has been active in the pet medication manufacturers sector through several key acquisitions: in 2021, Swedencare acquired Vetio for $181 million, enhancing its product offerings. In 2022, it completed the acquisition of NaturVet for $447.5 million, known for its therapy supplements for pets. Additionally, Swedencare acquired Ecuphar Ltd in 2016, which expanded its distribution network across Europe and beyond. These strategic acquisitions underline Swedencare's commitment to the pet healthcare market and its role as a significant player in the pet medication industry.


13. VetPartners Limited

  • Website: vetpartners.co.uk
  • Type: Corporate
  • Headquarters: York, England, United Kingdom (UK)
  • Founded year: 2015
  • Headcount: 5001-10000
  • Number of deals in 2024: 1
  • LinkedIn: vetpartners-limited

VetPartners Limited is a corporate investor based in York, England, founded in 2015. The company operates as a veterinary practice group, providing high-quality veterinary care and support to pet owners and farmers across the UK. With a network of practices, VetPartners focuses on specialized services tailored to the needs of their clients. In recent years, VetPartners has made several strategic acquisitions to expand its operations in the veterinary sector. Notably, they acquired VetUK Ltd, one of the UK's largest online pet care suppliers, in April 2021, which enhances their service offerings related to pet medications. Other significant acquisitions include Garston Veterinary Group in November 2023, New Era Veterinary Hospital in December 2019, and The Hyperthyroid Cat Centre in October 2020, which specializes in feline hyperthyroidism treatment. These transactions demonstrate VetPartners' commitment to enhancing veterinary services and access to pet medications, solidifying their position in the pet care industry.


14. Cvc

  • Website: cvc.com
  • Type: Private Equity
  • Headquarters: Luxembourg
  • Founded year: 2005
  • Headcount: 1001-5000
  • Number of deals in 2024: 16
  • LinkedIn: cvc-capital-partners

CVC Capital Partners is a prominent private equity investment firm based in Luxembourg, founded in 2005. It specializes in private equity, credit, secondaries, and infrastructure, managing approximately €193 billion in assets for over 1000 clients, including pension funds and institutional investors. CVC focuses on delivering sustainable value and growth through strategic investments. Notably, CVC has made significant investments in the pet industry, including the acquisition of a majority stake in Medivet, a veterinary group, for over £1 billion, which is expected to enhance its growth strategy in the UK and Europe. Additionally, CVC acquired Petco, a leading pet retailer, for $4.6 billion in 2016, further emphasizing its commitment to the pet sector. These transactions highlight CVC's active role in the pet medication and healthcare market.


15. Bgf

  • Website: bgf.co.uk
  • Type: Venture Capital
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 2011
  • Headcount: 51-200
  • Number of deals in 2024: 53
  • LinkedIn: bgfinvestments

BGF Investment Management Limited is a venture capital firm based in London, UK, founded in 2011. The firm specializes in providing growth funding and value creation support to small and mid-sized businesses across various sectors in the UK and Ireland. BGF focuses on addressing the funding gap in the market through minority investments and extensive support services. Notably, BGF has invested in Scrumbles, a London-based natural pet food brand, raising £6M in funding in March 2023, which highlights their involvement in the pet industry. This investment aligns with their strategy of supporting businesses that have potential for growth, including those in the pet medication and care sector. Other investments in their portfolio, while not directly related to pet medication, showcase their diverse investment approach.


16. Development Bank of Wales


The Development Bank of Wales is a public entity established in 2001 that provides financial support to Welsh businesses through loans and equity investments. Its mission is to facilitate business growth and economic development in Wales by offering various financial products tailored to the needs of small and medium-sized enterprises. In recent years, the bank has been active in the healthcare sector, with notable transactions including investments in Biomonde, which has developed treatments for hard-to-treat wounds, and Curapel, a healthcare company focused on developing and commercializing medical products. These investments highlight the bank's engagement in the healthcare industry, which may encompass areas relevant to pet medication manufacturers.


17. IK Partners

  • Website: ikpartners.com
  • Type: Private Equity
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 1989
  • Headcount: 201-500
  • Number of deals in 2024: 14
  • LinkedIn: ik-investment-partners

IK Partners is a private equity firm based in London, England, specializing in mid-market investments across Europe. Founded in 1989, the firm focuses on providing capital and strategic support to businesses in various sectors, including Business Services, Healthcare, Consumer, and Industrials. Notably, IK Partners has made significant investments in the pet medication industry, including the acquisition of CEVA Santé Animale, a leading company in animal health, which they acquired in 2003. They also acquired Innovad, a company involved in animal nutrition and health, in 2021. These transactions highlight IK Partners' commitment to enhancing growth and creating long-term value in the pet medication sector, making them a relevant investor in this field.


18. Portugal Ventures


Portugal Ventures is a venture capital firm based in Porto, Portugal, founded in 2012. The firm specializes in investing in startups with global ambitions, primarily located in Portugal, and provides both capital and strategic support to help these startups grow and scale their operations. Portugal Ventures focuses on innovative projects across various sectors, including technology and health. Notably, they have invested in Barkyn, a company that has raised significant funding to enhance its pet-related products and services, and Petable, which also operates in the pet sector. These transactions highlight Portugal Ventures' commitment to fostering entrepreneurship in the pet industry, particularly in areas that may intersect with pet health and medication.



Pet Medication Manufacturers Insights: Key Investors in Europe


InvestorHeadquarterSizeFoundedDeals 2024
CVS Group plcDiss, England, United Kingdom (UK)5001-1000019991
Bpifrance French Tech AccélérationParis, Île-De-France, France1-102015198
Novo HoldingsHellerup, Denmark51-200199945
AlmiStockholm, Stockholm, Sweden201-50019947
Enterprise IrelandDublin, Dublin, Ireland501-1000199848
CrowdcubeLondon, England, United Kingdom (UK)51-20020103
Scottish EnterpriseGlasgow, Scotland, United Kingdom (UK)1001-5000199155
Andera PartnersParis, Île-De-France, France51-200195310
Seventure PartnersParis, Île-De-France, France11-50199721
EQT GroupStockholm, Stockholm, Sweden1001-5000199430
3i Group plcLondon, England, United Kingdom (UK)201-50019453
SwedencareMalmo, Skåne, Sweden11-5020001
VetPartners LimitedYork, England, United Kingdom (UK)5001-1000020151
CvcLuxembourg1001-5000200516
BgfLondon, England, United Kingdom (UK)51-200201153
Development Bank of WalesWrexham, Wales, United Kingdom (UK)201-500200126
IK PartnersLondon, England, United Kingdom (UK)201-500198914
Portugal VenturesPorto, Porto, Portugal11-5020126


Want to find more investors focusing on the pet medication manufacturers industry?

If you want to find more investors that are active in the pet medication manufacturersindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!